Beta Drugs
Beta Drugs Limited, founded in 1985 and part of the Adley Group, is a pioneering oncology medicine manufacturer committed to delivering high-quality, affordable cancer and skin condition treatments worldwide. With a focus on innovation, research, and global expansion, the company aims to improve patient outcomes through advanced pharmaceuticals and strategic partnerships. The company maintains a robust financial and operational profile, with detailed annual reports, strategic updates, and a strong presence in the pharmaceutical industry.
Industries
Nr. of Employees
small (1-50)
Beta Drugs
SCO 184, Sector - 5, Panchkula, Haryana - 134114
Products
Temozolomide
Therapeutic class: alkylating agent
Vinorelbine
Therapeutic class: vinca alkaloid
Etoposide
Therapeutic class: topoisomerase II inhibitor
Doxorubicin
Therapeutic class: cytotoxic anthracycline antibiotic
Epirubicin
Therapeutic class: anthracycline topoisomerase II inhibitor
Leucovorin calcium
Therapeutic class: folic acid analog
Temozolomide
Therapeutic class: alkylating agent
Vinorelbine
Therapeutic class: vinca alkaloid
Etoposide
Therapeutic class: topoisomerase II inhibitor
Doxorubicin
Therapeutic class: cytotoxic anthracycline antibiotic
Epirubicin
Therapeutic class: anthracycline topoisomerase II inhibitor
Leucovorin calcium
Therapeutic class: folic acid analog
Services
On-site CDMO services covering API production and finished-dose manufacturing for oncology and supportive-care products, including client-dedicated operational support.
Process research and optimisation from laboratory to commercial scale, including novel synthesis route development and cost-reduction strategies.
Development services for liposomes, nanoparticles, microparticulates and protein-bound nanoparticle injectables with pathways toward commercialization.
Advisory and project-based support for technology transfer, licensing and international product registrations.
On-site laboratory testing for raw materials, in-process samples and finished products, including microbiological testing and analytical method documentation.
Manufacturing services for topical dermatology and cosmeceutical products alongside pharmaceutical product lines.
On-site CDMO services covering API production and finished-dose manufacturing for oncology and supportive-care products, including client-dedicated operational support.
Process research and optimisation from laboratory to commercial scale, including novel synthesis route development and cost-reduction strategies.
Development services for liposomes, nanoparticles, microparticulates and protein-bound nanoparticle injectables with pathways toward commercialization.
Advisory and project-based support for technology transfer, licensing and international product registrations.
On-site laboratory testing for raw materials, in-process samples and finished products, including microbiological testing and analytical method documentation.
Manufacturing services for topical dermatology and cosmeceutical products alongside pharmaceutical product lines.
Expertise Areas
- API development and process chemistry
- Formulation and finished-dosage manufacturing (parenteral, oral, lyophilized, RTU/prefilled)
- Novel drug delivery systems and nanoparticle formulations
- Targeted oncology small-molecule development (including PARP inhibitors)
Key Technologies
- Nanoparticle drug delivery
- Liposome formulation
- Microparticulate formulations
- Lyophilization (freeze-drying)
News & Updates
In December 2023, Beta Drugs Limited established a dedicated oral suspension plant for cancer medicines, setting a new industry standard.
In November 2023, Beta Drugs Limited was recognized on Forbes' list of the 200 best companies under a billion dollars.
In March 2021, Beta Drugs Limited introduced India's first NDDS formulation of Megestrol Acetate Suspension.
Recognition for Industry Leadership
Beta Drugs Limited has received multiple awards for excellence in pharmaceutical manufacturing.
In December 2023, Beta Drugs Limited established a dedicated oral suspension plant for cancer medicines, setting a new industry standard.
In November 2023, Beta Drugs Limited was recognized on Forbes' list of the 200 best companies under a billion dollars.
In March 2021, Beta Drugs Limited introduced India's first NDDS formulation of Megestrol Acetate Suspension.
Recognition for Industry Leadership
Beta Drugs Limited has received multiple awards for excellence in pharmaceutical manufacturing.